Last week a panel of judges at the U.S. Patent and Trademark Office in Alexandria, Virginia, heard arguments as to who should own the rights to the century’s biggest biotechnology invention to date, a precise gene-editing system called CRISPR-Cas9 that has the potential to treat serious human genetic disorders and create designer crops that resist […]